Research Topics
| Yves PerelSummaryAffiliation: CHU de Bordeaux Country: France Publications
| Collaborators
|
Detail Information
Publications
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 studyVirginie Gandemer
Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France
BMC Cancer 9:14. 2009..Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors...
Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation statusY Perel
Laboratory of Differentiation and Development Biology, EA DRED 483, University of Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
Br J Cancer 86:117-22. 2002..Finally, our results suggest that galanin influences neuroblastoma growth and development as an autocrine/paracrine modulator. These findings suggest potential critical implications for galanin in neuroblastic tumours development...
Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapyYves Perel
Department of Pediatrics, Onco Hematology Unit, University Hospital, 33076 Bordeaux, France
Pediatrics 109:1170-3. 2002..In some cases of Gaucher's disease, alternative strategies such as fractionated or further increased ERT, gene therapy, or glucosyltransferase inhibitor should be explored...
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde EnfantYves Perel
Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Centres Hospitalo Universitaires de Bordeaux, France
J Clin Oncol 20:2774-82. 2002..To determine whether the use of maintenance therapy (MT) delivered after intensive induction and consolidation therapy confers any advantage in childhood acute myeloid leukemia (AML)...
Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative GroupY Perel
Pediatric Onco Hematology Unit, University Hospital, Bordeaux, France
Leukemia 19:2082-9. 2005..6+/-8 vs 59+/-8%; P=0.05), while the 5-year DFS was not significantly different. Exposure to low-dose MT might contribute to clinical drug resistance and treatment failure in relapsing patients...
[Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]Y Perel
Unité d oncohématologie pédiatrique, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, CHU de Bordeaux, 33076 Bordeaux, France
Arch Pediatr 11:834-42. 2004..Recent advances in understanding the biology and genetics of neuroblastoma will ultimately allow to select poor-risk patients for appropriate future biologically based therapies...
A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of ageSylvie Monnereau-Laborde
Department of Pediatric Hemato Oncology, CHU Bordeaux, Children s Hospital, Place Amelie Rabat Leon, Bordeaux, France
Pediatr Blood Cancer 57:965-71. 2011..To improve outcome and overall survival (OS) in high-risk neuroblastoma, NB96 induction therapy was intensified using sequential high-dose chemotherapy and autologous stem cell rescue...
Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and ImmunologyNathalie Aladjidi
Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Place Amelie Raba Leon, 33076 Bordeaux, France
J Clin Oncol 21:4377-85. 2003..The goals of this retrospective study were to determine whether these children could be treated successfully with a salvage regimen and to establish the optimal therapeutic strategy...
High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplificationAnne Laprie
Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
Cancer 101:1081-9. 2004..The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA)...
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocolDominique Valteau-Couanet
Departement de Pediatrie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Oncol 23:532-40. 2005..To test the metastatic response rate in stage 4 neuroblastoma, using dose-intensive induction chemotherapy in a multi-institutional setting...
Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003Julie Tandonnet
Bordeaux University and Bordeaux University Hospital, Pediatric Oncology and Hematology Unit, 33076 Bordeaux, France
Pediatr Blood Cancer 54:927-33. 2010..To determine the epidemiology of myeloid leukaemia (ML) in children with Down syndrome (DS) and the efficacy of two approaches, low-dose cytarabine-based regimen (LDC) and standard-dose intensive chemotherapy (SD)...
Ectopic Cushing's syndrome due to an adrenal ganglioneuromaJean Benoit Corcuff
Department of Nuclear Medicine, CHU Bordeaux, Bordeaux, France
Horm Res Paediatr 73:405-8. 2010..Cortical cell hyperplasia was observed. Conclusion: Benign and differentiated tumors of the neural crest such as ganglioneuromas may be responsible for CS...
Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 studyCaroline Oudot
Service d hématologie et oncologie pédiatrique, Hopital Mere Enfant, Limoges, France
J Clin Oncol 26:1496-503. 2008..To identify prognostic factors and to evaluate the outcome of children with acute lymphoblastic leukemia (ALL) failure after induction therapy...
Rituximab therapy for childhood Evans syndromeBrigitte Bader-Meunier
Assistance Publique Hopitaux de Paris, Service d hématologie oncologie pédiatrique, Hopital Robert Debre, Paris, France
Haematologica 92:1691-4. 2007..4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively...
Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE)Nathalie Mallol Mesnard
INSERM U754, IFR69, 16 Avenue Paul Vaillant Couturier, F 94807 Villejuif Cedex, France
Int J Epidemiol 36:110-6. 2007..Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study...
Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trialsNicolas Boissel
Services d Hématologie Pédiatrique et Adulte, Laboratoire Central d Hématologie, Hopital Saint Louis, France
J Clin Oncol 21:774-80. 2003..To compare pediatric and adult therapeutic practices in the treatment of acute lymphoblastic leukemia (ALL) in adolescents...
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcomePaola Ballerini
Laboratoire d Hematologie, Hopital A Trousseau, INSERM E0210
Haematologica 93:1658-65. 2008..Likewise, the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia of the newly characterized NUP214-ABL1 fusion transcript is not yet clear...
An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised childrenDavid Nadal
Division of Infectious Diseases, University Children s Hospital of Zurich, CH 8032 Zurich, Switzerland
J Infect Dis 186:S123-30. 2002..In general, adverse events were not attributable to valacyclovir and were consistent with disease-related expectations and concomitant therapies. Dosage options for using valacyclovir in children are discussed...
Comparative values of catecholamines and metabolites for the diagnosis of neuroblastomaMaud Monsaingeon
, , 33604 Pessac, France
Eur J Pediatr 162:397-402. 2003..Plotting individual levels (normetanephrine versus vanillylmandelic acid or homovanillic acid) allowed a rapid visual analysis that would have missed only one small low grade non-secreting tumour...
Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemiaJean Delorme
Department of Pharmacy, Research Unit INSERM No. 379, France
J Pediatr Hematol Oncol 25:441-7. 2003..The cost benefit of prophylactic treatment by G-CSF relies on the chemotherapeutic regimen given prior to G-CSF administration...
A 22-year French experience with solid tumors in children with Down syndromeDaniel Satgé
Laboratoire d Anatomie Pathologique, Centre Hospitalier, Tulle, France
Pediatr Hematol Oncol 20:517-29. 2003..The treatment of solid tumors in DS is difficult, due to physical and psychological impairments, different pharmacogenetic profile, and associated malformations...
